O	0	1	A
O	2	8	single
O	8	9	-
O	9	15	center
O	15	16	,
O	17	28	prospective
O	29	32	and
O	33	43	randomized
O	44	54	controlled
O	55	60	study
O	60	61	:
O	62	65	Can
O	66	69	the
O	70	82	prophylactic
O	83	86	use
O	87	89	of
B-intervention	90	100	lamivudine
O	101	108	prevent
B-condition	109	118	hepatitis
I-condition	119	120	B
I-condition	121	126	virus
I-condition	127	139	reactivation
O	140	142	in
B-eligibility	143	152	hepatitis
I-eligibility	153	154	B
I-eligibility	155	156	s
I-eligibility	156	157	-
I-eligibility	157	164	antigen
I-eligibility	165	177	seropositive
I-eligibility	178	184	breast
I-eligibility	185	191	cancer
I-eligibility	192	200	patients
O	201	207	during
O	208	220	chemotherapy
O	220	221	?

O	222	226	Over
O	227	230	the
O	231	235	past
O	236	240	four
O	241	248	decades
O	248	249	,
O	250	262	chemotherapy
O	263	266	has
O	267	273	played
O	274	276	an
O	277	286	important
O	287	291	role
O	292	294	in
O	295	305	prolonging
O	306	314	survival
O	315	317	in
O	318	324	breast
O	325	331	cancer
O	332	340	patients
O	340	341	.

O	342	349	However
O	349	350	,
O	351	353	it
O	354	357	may
O	358	362	also
O	363	369	result
O	370	372	in
O	373	384	undesirable
O	385	389	side
O	390	397	effects
O	398	402	such
O	403	405	as
O	406	415	hepatitis
O	416	417	B
O	418	423	virus
O	424	425	(
O	425	428	HBV
O	428	429	)
O	430	442	reactivation
O	443	447	seen
O	448	450	in
O	451	455	this
O	456	461	study
O	461	462	.

O	463	467	With
O	468	471	the
O	472	482	increasing
O	483	486	use
O	487	489	of
O	490	502	chemotherapy
O	503	514	paralleling
O	515	518	the
O	519	523	rise
O	524	526	in
O	527	533	breast
O	534	540	cancer
O	541	550	incidence
O	550	551	,
O	552	555	the
O	556	566	occurrence
O	567	569	of
O	570	573	HBV
O	574	586	reactivation
O	587	589	is
O	590	596	likely
O	597	599	to
O	600	607	further
O	608	616	increase
O	616	617	.

O	618	625	Several
O	626	636	strategies
O	637	640	use
O	641	651	lamivudine
O	652	654	to
O	655	659	deal
O	660	664	with
O	665	669	this
O	670	677	problem
O	677	678	.

O	679	688	Initially
O	688	689	,
O	690	700	lamivudine
O	701	704	had
O	705	709	been
O	710	714	used
O	715	717	to
O	718	723	treat
O	724	732	patients
O	733	736	who
O	737	746	developed
O	747	754	alanine
O	755	767	transaminase
O	768	777	elevation
O	778	790	attributable
O	791	793	to
O	794	797	HBV
O	798	810	reactivation
O	811	817	during
O	818	830	chemotherapy
O	830	831	.

O	832	839	However
O	839	840	,
O	841	846	using
O	847	851	this
O	852	860	strategy
O	860	861	,
O	862	867	fatal
O	868	880	reactivation
O	881	884	has
O	885	889	also
O	890	894	been
O	895	903	reported
O	903	904	.

O	905	910	Later
O	911	918	studies
O	919	923	have
O	924	933	suggested
O	934	938	that
O	939	951	prophylactic
O	952	962	lamivudine
O	963	976	significantly
O	977	984	reduces
O	985	988	HBV
O	989	1001	reactivation
O	1002	1005	and
O	1006	1009	its
O	1010	1020	associated
O	1021	1030	morbidity
O	1030	1031	.

O	1032	1039	However
O	1039	1040	,
O	1041	1046	these
O	1047	1054	studies
O	1055	1059	were
O	1060	1065	based
O	1066	1072	mainly
O	1073	1075	on
O	1076	1084	patients
O	1085	1089	with
O	1090	1098	lymphoma
O	1098	1099	,
O	1100	1107	whereas
O	1108	1115	studies
O	1116	1118	on
O	1119	1125	breast
O	1126	1132	cancer
O	1133	1141	patients
O	1142	1146	were
O	1147	1150	few
O	1150	1151	.

O	1152	1160	Moreover
O	1160	1161	,
O	1162	1167	these
O	1168	1175	studies
O	1176	1180	were
O	1181	1194	retrospective
O	1194	1195	.

O	1196	1204	Recently
O	1204	1205	,
O	1206	1207	a
O	1208	1219	prospective
O	1220	1225	study
O	1226	1229	has
O	1230	1241	recommended
O	1242	1246	that
O	1247	1255	deferred
O	1256	1266	preemptive
O	1267	1277	lamivudine
O	1278	1283	could
O	1284	1286	be
O	1287	1288	a
O	1289	1299	comparable
O	1300	1311	alternative
O	1312	1314	to
O	1315	1318	the
O	1319	1331	prophylactic
O	1332	1340	strategy
O	1340	1341	.

O	1342	1349	However
O	1349	1350	,
O	1351	1353	it
O	1354	1357	was
O	1358	1361	not
O	1362	1363	a
O	1364	1374	randomized
O	1375	1385	controlled
O	1386	1391	study
O	1391	1392	.

O	1393	1395	In
O	1396	1400	this
O	1401	1406	study
O	1406	1407	,
O	1408	1410	it
O	1411	1414	was
O	1415	1423	examined
O	1424	1427	the
O	1428	1436	efficacy
O	1437	1439	of
O	1440	1443	the
O	1444	1456	prophylactic
O	1457	1465	strategy
O	1466	1468	in
O	1469	1478	hepatitis
O	1479	1480	B
O	1481	1482	s
O	1482	1483	-
O	1483	1490	antigen
O	1491	1503	seropositive
O	1504	1510	breast
O	1511	1517	cancer
O	1518	1526	patients
O	1527	1533	during
O	1534	1546	chemotherapy
O	1547	1552	using
O	1553	1554	a
O	1555	1566	prospective
O	1566	1567	,
O	1568	1578	randomized
O	1579	1589	controlled
O	1590	1595	study
O	1595	1596	.

O	1597	1600	Two
O	1601	1607	groups
O	1608	1612	were
O	1613	1620	studied
O	1620	1621	.

O	1622	1625	One
O	1626	1631	group
O	1632	1641	consisted
O	1642	1644	of
B-intervention-participants	1645	1647	21
O	1648	1656	patients
O	1657	1660	who
O	1661	1665	were
O	1666	1673	treated
O	1674	1678	with
O	1679	1691	prophylactic
O	1692	1702	lamivudine
O	1702	1703	,
O	1704	1707	the
O	1708	1713	other
O	1714	1719	group
O	1720	1729	consisted
O	1730	1732	of
B-control-participants	1733	1735	21
O	1736	1744	patients
O	1745	1748	who
O	1749	1753	were
B-control	1754	1757	not
I-control	1758	1765	treated
I-control	1766	1770	with
I-control	1771	1783	prophylactic
I-control	1784	1794	lamivudine
O	1794	1795	.

O	1796	1799	The
O	1800	1807	results
O	1808	1814	showed
O	1815	1819	that
O	1820	1823	the
O	1824	1836	prophylactic
O	1837	1847	lamivudine
O	1848	1856	strategy
O	1857	1870	significantly
O	1871	1880	decreased
O	1881	1884	the
B-outcome	1885	1894	incidence
I-outcome	1895	1897	of
I-outcome	1898	1901	HBV
I-outcome	1902	1914	reactivation
O	1915	1916	(
B-iv-bin-percent	1916	1917	0
O	1918	1920	vs
O	1920	1921	.
B-cv-bin-percent	1922	1924	28
I-cv-bin-percent	1924	1925	.
I-cv-bin-percent	1925	1926	6
I-cv-bin-percent	1926	1927	%
O	1927	1928	,
O	1929	1930	P
O	1931	1932	=
O	1933	1934	0
O	1934	1935	.
O	1935	1938	021
O	1938	1939	)
O	1939	1940	.

O	1941	1943	It
O	1944	1947	was
O	1948	1956	conclude
O	1957	1961	that
O	1962	1965	the
O	1966	1978	prophylactic
O	1979	1989	lamivudine
O	1990	1998	strategy
O	1999	2012	significantly
O	2013	2020	reduces
O	2021	2024	the
O	2025	2034	incidence
O	2035	2037	of
O	2038	2041	HBV
O	2042	2054	reactivation
O	2055	2058	for
O	2059	2068	hepatitis
O	2069	2070	B
O	2071	2072	s
O	2072	2073	-
O	2073	2080	antigen
O	2081	2093	seropositive
O	2094	2100	breast
O	2101	2107	cancer
O	2108	2118	undergoing
O	2119	2131	chemotherapy
O	2131	2132	.
